South Berwick Pharmacy Seacoast Compounding, Inc., South Berwick, ME
Is South Berwick Pharmacy Seacoast Compounding, Inc. registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does South Berwick Pharmacy Seacoast Compounding, Inc. hold a Maine pharmacy license?
State board of pharmacy records for Maine are not checked: this index has not yet added that board’s records.
Has South Berwick Pharmacy Seacoast Compounding, Inc. had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 state referral letter (Jun 14, 2023) and 1 FMD-145 letter (Jun 14, 2023) for South Berwick Pharmacy Seacoast Compounding, Inc. State board of pharmacy records for Maine are not checked: this index has not yet added that board’s records. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- South Berwick Pharmacy Seacoast Compounding, Inc.
- Location
- South Berwick, ME
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Jun 14, 2023
- FDA Data Dashboard inspections
- 1 inspection: 1 VAI; 1 published Form 483
- Form 483 text on this page
- 1 Form 483, 4 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as South Berwick Pharmacy Seacoast Compounding, Inc., a 503A facility, with 3 dated actions.
| Document | |||
|---|---|---|---|
| Jun 14, 2023 | State referral letter | State Referral Letter Issued 6/14/2023 | Not linked by FDA |
| Jun 14, 2023 | FMD-145 letter | FMD-145 Letter Issued 06/14/2023 | Not linked by FDA |
| Sep 30, 2022 | Form 483 | 483 Issued 09/30/2022 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists South Berwick Pharmacy Seacoast Compounding, Inc., South Berwick, ME (FEI number 3005636572), matched to this page by exact name, city and state. It lists 1 inspection: 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Sep 30, 2022 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs): Voluntary Action Indicated (VAI); Monitoring of Marketed Animal Drugs, Feed, and Devices (Veterinary): Voluntary Action Indicated (VAI) | 3005636572 | 1180923 |
Form 483s FDA has published for this site
- Sep 30, 2022: Form 483 to South Berwick Pharmacy Seacoast Compounding, Inc., published Dec 20, 2022. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 4 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Sep 12, 2022 to Sep 30, 2022: 4 observations
- Firm on the cover
- South Berwick Pharmacy Seacoast Compounding, Inc., 289 Main St, South Berwick, ME 03908-1543
- FEI number
- 3005636572
- Establishment type on the cover
- Producer of Non-Sterile Drugs
- FDA district office on the cover
- One Montvale Avenue Stoneham, MA 02180
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
You produced hazardous drug; without providing adequate containment, segregation, cleaning of work surfaces and cleaning of utensils to prevent cross-contamination.
Specifically,
D Your firm utilizes a <Redacted B4> biological safety cabinet for the production of both hazardous and non-hazardous drug products. Cleaning of the interior of the biological safety cabinet consists only of a wiping with <Redacted B4> before and after each batch production The firm produces the following non-sterile hazardous drug products:; Colchicine, Cyclosporine, Methimazole, Tacrolimus. In addition, the firm produces the following hormones, antibiotics and highly potent drug;: Estradiol, Estrone Progesterone, Testosterone, Enrofloxacin, Doxycycline Hyclate and Clobetasol. The firm has no assurance that the current cleaning method is effective at removing hazardous drug residues on surfaces nor does the firm have a formal decontamination procedure for use following the production of hazardous drug products. ...
Observation 2
Non-microbial contamination was observed in your production area.
Specifically,
D A yellow crusty substance was observed on the HEPA filter within the <Redacted B4> biological safety cabinet <Redacted B4>. In addition, opaque residues were noted on the interior walls of the biological safety cabinet. The aforementioned cabinet 1s utilized for the production of all hazardous and non-hazardous non-sterile drug products .
D Light brownish stains were noted on the interior of the firm's <Redacted B4> located inside of the <Redacted B4> (biological safety cabinet), the base of the <Redacted B4> face of the <Redacted B4> sealer <Redacted B4> and on the front of the <Redacted B4>. The aforementioned equipment are utilized in the production of the firm's non-sterile drug products.
D Heavy dust buildup was noted on top of the <Redacted B4> biological safety cabinet and cobwebs were observed on the walls within the production room.
Observation 3
Vermin was observed in your production area.
Specifically,
Dead insects were observed behind the <Redacted B4> front facing of the <Redacted B4> biological safety cabinet <Redacted B4>. In addition, several live flying insects were observed within the production area.
Observation 4
You used a non-pharmaceutical grade component in the formulation of a drug product.
Specifically,
D Your firm uses <Redacted B4> for use in production of non-sterile drug products. For example, the firm utilized <Redacted B4> instead of <Redacted B4> the production of <Redacted B4> lot# <Redacted B4>. The aforementioned lot of <Redacted B4> was used in the production of Ketaniine Nasal Spray lot# 0602202~ and lot# 08232022@ <Redacted B4>.
D Your firm released multiple lots of non-sterile drug products that were produced from expired components. There is no assurance that the expired components continue to meet pharmaceutical grade specifications. For example:
that the expired components continue to meet pharmaceutical grade specifications. For example:
1 You produced Oobetasol in Dermazinc 0.05 Solution lot 06232022@ <Redacted B4> on 6/23/2022 using Clobetasol Propionate USP Micronized lot <Redacted B4> with expiry 2/28/2021 as the APL This product was used to fill Rx <Redacted B4>, issued 6/23/2022.
2. ...
State board of pharmacy records
State board of pharmacy records for Maine are not checked: this index has not yet added that board’s records.
This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.